Shanghai Kehua Bio-Engineering Co Ltd
Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated co… Read more
Shanghai Kehua Bio-Engineering Co Ltd (002022) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.47 Billion CNY
Based on the latest financial reports, Shanghai Kehua Bio-Engineering Co Ltd (002022) has total liabilities worth CN¥1.47 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Kehua Bio-Engineering Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Shanghai Kehua Bio-Engineering Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanghai Kehua Bio-Engineering Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Kehua Bio-Engineering Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Wanlima Industry Co Ltd
SHE:300591
|
China | CN¥413.01 Million |
|
Beijing Hanbang Technology Corp
SHE:300449
|
China | CN¥157.86 Million |
|
Shenzhen Everbest Machinery Indus
SHE:002980
|
China | CN¥381.98 Million |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | ₹1.63 Billion |
|
Beta Bionics, Inc. Common Stock
NASDAQ:BBNX
|
USA | $39.59 Million |
|
Hana Tour
KO:039130
|
Korea | ₩563.00 Billion |
|
Anupam Rasayan India Limited
NSE:ANURAS
|
India | ₹22.01 Billion |
|
Shandong Homey Aquatic Development Co Ltd
SHG:600467
|
China | CN¥3.64 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Shanghai Kehua Bio-Engineering Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Kehua Bio-Engineering Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Kehua Bio-Engineering Co Ltd (2001–2024)
The table below shows the annual total liabilities of Shanghai Kehua Bio-Engineering Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.25 Billion | -31.25% |
| 2023-12-31 | CN¥1.82 Billion | -38.42% |
| 2022-12-31 | CN¥2.96 Billion | +62.35% |
| 2021-12-31 | CN¥1.82 Billion | -12.23% |
| 2020-12-31 | CN¥2.08 Billion | +104.87% |
| 2019-12-31 | CN¥1.01 Billion | -5.53% |
| 2018-12-31 | CN¥1.07 Billion | +68.70% |
| 2017-12-31 | CN¥636.48 Million | +50.66% |
| 2016-12-31 | CN¥422.47 Million | +22.11% |
| 2015-12-31 | CN¥345.97 Million | +114.37% |
| 2014-12-31 | CN¥161.39 Million | -0.43% |
| 2013-12-31 | CN¥162.08 Million | -18.57% |
| 2012-12-31 | CN¥199.05 Million | +13.17% |
| 2011-12-31 | CN¥175.89 Million | +13.06% |
| 2010-12-31 | CN¥155.58 Million | +16.95% |
| 2009-12-31 | CN¥133.03 Million | +42.18% |
| 2008-12-31 | CN¥93.56 Million | -25.84% |
| 2007-12-31 | CN¥126.16 Million | +45.91% |
| 2006-12-31 | CN¥86.46 Million | +13.29% |
| 2005-12-31 | CN¥76.32 Million | +20.16% |
| 2004-12-31 | CN¥63.51 Million | -22.84% |
| 2003-12-31 | CN¥82.31 Million | +3.81% |
| 2002-12-31 | CN¥79.29 Million | +115.22% |
| 2001-12-31 | CN¥36.84 Million | -- |